Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) – Analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Protagonist Therapeutics in a research report issued on Friday, November 6th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $4.61 for the year, up from their previous forecast of $4.00. HC Wainwright has a “Buy” rating and a $221.00 price target on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $4.59 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q4 2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.45) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at $0.31 EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at $0.67 EPS, FY2029 earnings at $7.60 EPS and FY2030 earnings at $7.78 EPS.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported $3.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.57. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%. The company had revenue of $274.41 million during the quarter, compared to analyst estimates of $238.49 million.
Several other equities research analysts also recently weighed in on PTGX. The Goldman Sachs Group raised shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $110.00 to $186.00 in a report on Monday, August 10th. Wedbush reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday. BMO Capital Markets raised their target price on shares of Protagonist Therapeutics from $178.00 to $190.00 and gave the company an “outperform” rating in a research note on Tuesday, September 1st. Johnson Rice set a $165.00 price target on shares of Protagonist Therapeutics in a research report on Friday, July 17th. Finally, Weiss Ratings upgraded shares of Protagonist Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $166.67.
Check Out Our Latest Research Report on PTGX
Protagonist Therapeutics Stock Performance
Shares of PTGX opened at $135.90 on Tuesday. The firm has a market capitalization of $8.79 billion, a price-to-earnings ratio of 28.79 and a beta of 1.21. Protagonist Therapeutics has a one year low of $77.00 and a one year high of $160.81. The stock’s fifty day moving average is $141.35 and its 200-day moving average is $118.09.
Insider Activity at Protagonist Therapeutics
In other news, CFO Asif Ali sold 58,629 shares of Protagonist Therapeutics stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total value of $8,312,419.62. Following the transaction, the chief financial officer directly owned 59,003 shares of the company’s stock, valued at $8,365,445.34. This trade represents a 49.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinsesh Patel sold 63,548 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the sale, the chief executive officer directly owned 522,968 shares in the company, valued at approximately $76,447,462.24. This trade represents a 10.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 183,629 shares of company stock worth $26,552,987. 5.19% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Protagonist Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of PTGX. Bessemer Group Inc. lifted its position in shares of Protagonist Therapeutics by 141.6% in the third quarter. Bessemer Group Inc. now owns 125,822 shares of the company’s stock worth $17,727,000 after purchasing an additional 73,748 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Protagonist Therapeutics by 42.8% during the third quarter. Hantz Financial Services Inc. now owns 1,438 shares of the company’s stock worth $203,000 after purchasing an additional 431 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Protagonist Therapeutics by 86.1% during the third quarter. Russell Investments Group Ltd. now owns 214,777 shares of the company’s stock worth $30,260,000 after purchasing an additional 99,352 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Protagonist Therapeutics by 3.7% during the third quarter. Fifth Third Bancorp now owns 13,597 shares of the company’s stock worth $1,916,000 after purchasing an additional 485 shares during the period. Finally, Maryland State Retirement & Pension System purchased a new position in Protagonist Therapeutics during the third quarter valued at approximately $2,032,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.
More Protagonist Therapeutics News
Here are the key news stories impacting Protagonist Therapeutics this week:
- Positive Sentiment: HC Wainwright raised estimates across several periods: FY2026 EPS to $4.61 from $4.00; FY2027 loss per share to $0.98 from $2.80; and FY2028 to profit of $0.67 from a projected loss of $2.45. Longer-term forecasts rose sharply, with FY2029 EPS revised to $7.60 from $0.12 and FY2030 to $7.78 from $1.46. The firm also now expects Q4 2027 EPS of $0.31, versus its prior loss estimate of $0.15.
- Positive Sentiment: HC Wainwright maintains a Buy rating and a $221 price target; a separate report says the target was raised to $221. Article: Protagonist Therapeutics Price Target Raised to $221.00
Protagonist Therapeutics Company Profile
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.
The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V.
Featured Articles
- Five stocks we like better than Protagonist Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
